

Mitch Earleywine

Advances in Psychotherapy –
Evidence-Based Practice

Substance Use Problems

2nd edition



 hogrefe

Substance Use Problems

2nd edition

About the Author

Mitch Earleywine, PhD, is Professor of Clinical Psychology at the University at Albany, State University of New York, where he teaches drugs and human behavior, substance abuse treatment, and clinical research methods. He has received over 20 teaching commendations, including the coveted General Education Teaching Award from the University of Southern California. His research funding has come from the National Institute on Alcohol Abuse and Alcoholism, the Alcoholic Beverage Medical Research Foundation, and the Marijuana Policy Project. He serves on the editorial boards of four psychology journals, reviews for over a dozen, and has more than 120 publications on drug use and abuse, including *Understanding Marijuana* (Oxford University Press, 2002). He served as Chair of the Board of Directors for the National Organization for the Reform of Marijuana Laws, and is a member of the Research Society on Alcoholism, the Association for the Advancement of Behavior Therapy, and the Drug Policy Alliance.

Advances in Psychotherapy – Evidence-Based Practice

Series Editor

Danny Wedding, PhD, MPH, School of Medicine, American University of Antigua, St. Georges, Antigua

Associate Editors

Larry Beutler, PhD, Professor, Palo Alto University / Pacific Graduate School of Psychology, Palo Alto, CA

Kenneth E. Freedland, PhD, Professor of Psychiatry and Psychology, Washington University School of Medicine, St. Louis, MO

Linda C. Sobell, PhD, ABPP, Professor, Center for Psychological Studies, Nova Southeastern University, Ft. Lauderdale, FL

David A. Wolfe, PhD, RBC Chair in Children's Mental Health, Centre for Addiction and Mental Health, University of Toronto, ON

The basic objective of this series is to provide therapists with practical, evidence-based treatment guidance for the most common disorders seen in clinical practice – and to do so in a reader-friendly manner. Each book in the series is both a compact “how-to” reference on a particular disorder for use by professional clinicians in their daily work and an ideal educational resource for students as well as for practice-oriented continuing education.

The most important feature of the books is that they are practical and easy to use: All are structured similarly and all provide a compact and easy-to-follow guide to all aspects that are relevant in real-life practice. Tables, boxed clinical “pearls,” marginal notes, and summary boxes assist orientation, while checklists provide tools for use in daily practice.

Substance Use Problems

2nd edition

Mitch Earleywine

Psychology Department, Clinical Area, University at Albany, State University of New York, NY



Library of Congress Cataloging in Publication information for the print version of this book is available via the Library of Congress Marc Database under the Library of Congress Control Number 2016933580

Library and Archives Canada Cataloguing in Publication

Earleywine, Mitch, author

Substance use problems / Mitch Earleywine (Psychology Department, Clinical Area, University at Albany, State University of New York, NY). -- 2nd edition.

(Advances in psychotherapy--evidence-based practice volume 15)

Includes bibliographical references.

Issued in print and electronic formats.

ISBN 978-0-88937-416-4 (paperback).--ISBN 978-1-61676-416-6 (pdf).--

ISBN 978-1-61334-416-3 (epub)

1. Drug abuse. 2. Drug abuse--Treatment. I. Title. II. Series: Advances in psychotherapy--evidence-based practice ; v. 15

RC564.E25 2016

616.86'0651

C2016-901276-X

C2016-901277-8

Cover image © iStock.com/monkeybusinessimages

© 2016 by Hogrefe Publishing

<http://www.hogrefe.com>

PUBLISHING OFFICES

USA: Hogrefe Publishing Corporation, 38 Chauncy Street, Suite 1002, Boston, MA 02111
Phone (866) 823-4726, Fax (617) 354-6875; E-mail customerservice@hogrefe.com

EUROPE: Hogrefe Publishing GmbH, Merkelstr. 3, 37085 Göttingen, Germany
Phone +49 551 99950-0, Fax +49 551 99950-111; E-mail publishing@hogrefe.com

SALES & DISTRIBUTION

USA: Hogrefe Publishing, Customer Services Department, 30 Amberwood Parkway, Ashland, OH 44805
Phone (800) 228-3749, Fax (419) 281-6883; E-mail customerservice@hogrefe.com

UK: Hogrefe Publishing, c/o Marston Book Services Ltd., 160 Eastern Ave.,
Milton Park, Abingdon, OX14 4SB, UK
Phone +44 1235 465577, Fax +44 1235 465556; E-mail direct.orders@marston.co.uk

EUROPE: Hogrefe Publishing, Merkelstr. 3, 37085 Göttingen, Germany
Phone +49 551 99950-0, Fax +49 551 99950-111; E-mail publishing@hogrefe.com

OTHER OFFICES

CANADA: Hogrefe Publishing, 660 Eglinton Ave. East, Suite 119-514, Toronto, Ontario, M4G 2K2

SWITZERLAND: Hogrefe Publishing, Länggass-Strasse 76, CH-3000 Bern 9

Copyright Information

The e-book, including all its individual chapters, is protected under international copyright law. The unauthorized use or distribution of copyrighted or proprietary content is illegal and could subject the purchaser to substantial damages. The user agrees to recognize and uphold the copyright.

License Agreement

The purchaser is granted a single, nontransferable license for the personal use of the e-book and all related files.

Making copies or printouts and storing a backup copy of the e-book on another device is permitted for private, personal use only.

Other than as stated in this License Agreement, you may not copy, print, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit any of the e-book's content, in whole or in part, and you may not aid or permit others to do so. You shall not: (1) rent, assign, timeshare, distribute, or transfer all or part of the e-book or any rights granted by this License Agreement to any other person; (2) duplicate the e-book, except for reasonable backup copies; (3) remove any proprietary or copyright notices, digital watermarks, labels, or other marks from the e-book or its contents; (4) transfer or sublicense title to the e-book to any other party.

These conditions are also applicable to any audio or other files belonging to the e-book. Should the print edition of this book include electronic supplementary material then all this material (e.g., audio, video, pdf files) is also available in the e-book-edition.

Format: PDF

ISBN 978-0-88937-416-4 (print) • ISBN 978-1-61676-416-6 (PDF) • ISBN 978-1-61334-416-3 (EPUB)

<http://doi.org/10.1027/00416-000>

Acknowledgments

My hearty thanks to Danny Wedding, Robert Dimbleby, and Linda Sobell for keeping me involved in this project. I thank my clinical supervisees who encouraged me to elaborate on these points. The graduate students who took the substance abuse treatment course in the last 26 years deserve congratulations for keeping me on top of this literature while encouraging me to explain it efficiently. The thousands (!) who took the infamous “Drug Class” kept me excited about these topics by letting me see this field through their eyes. My usual support team also gets unusual kudos: Robert Earleywine, the late Clark and Suzy Van Scoyk, David and Felice Gordis, Joe Earleywine (who critiqued sections with great candor and minimal ridicule), Jack Huntington, Paul Armentano, Allen St. Pierre, Keith Stroup, Rick Steves, and Domenico Scarlatti. My unbridled thanks to Nicholas Van Dam, who deserves an award for reading every word of this document and many that didn’t make it. His comments improved the book dramatically. Special thanks to Michelle Stiles, who turned my free associations into references. I also thank my new support team: The Musketeers (Brad Armour-Garb, Tony DeBlasi, and Larry Kranich), and Russ Belville also get my sincere gratitude. My unparalleled gratitude also goes to Joey Palamar for computing the alcohol statistics for Table 2.

My daughters, Dahlia and Maya, continue to teach me that no matter how much I may know about genetics and environment, I cannot explain all the variance in behavior. My wife, Elana, continues to show inexplicable support, including astounding clinical skill at dealing with frequent and severe bouts of DMS (drug manuscript syndrome). I dedicate this book to her with love.

But I think I owe the biggest debt to the clients who sat with me as we all crawled, walked, ran, and occasionally flew toward better lives.

Table of Contents

Acknowledgments	v
1 Description	1
1.1 Terminology	1
1.1.1 Diagnostic Terms	1
1.1.2 Common Drugs	3
1.1.3 Nonproblematic, Recreational Drug Use.	5
1.1.4 Problematic Drug Use	6
1.2 Definitions	7
1.2.1 Substance-Related and Addictive Disorders	7
1.2.2 Codes From the DSM	9
1.2.3 Drug Problems	9
1.3 Epidemiology	10
1.3.1 World Statistics	10
1.3.2 Demographic Correlates	11
1.3.3 Recent Use	12
1.3.4 Problematic Use.	12
1.4 Course and Prognosis	12
1.4.1 Chronicity	13
1.5 Differential Diagnosis	13
1.5.1 Deviant Arousal	13
1.5.2 Thought Disorder.	14
1.6 Comorbidities.	14
1.6.1 Impulse Control Disorders	15
1.6.2 Problem Gambling	15
1.6.3 Eating Disorders	16
1.6.4 Attention Deficit Disorders	16
1.6.5 Conduct Disorder.	16
1.6.6 Personality Disorders.	17
1.6.7 Mood Disorders	18
1.6.8 Anxiety Disorders	18
1.6.9 Suicide	18
1.7 Diagnostic Procedures and Documentation.	19
2 The Biopsychosocial Model of Drug Problems	21
2.1 Interacting Components.	22
2.2 Initiation.	23
2.3 Regular Use	23
2.4 Problem Use.	24
2.5 Treatment Outcomes	24
3 Diagnosis, Assessment, and Treatment Indications	27
3.1 Assessment <i>Is</i> Treatment	27
3.2 Timeline Followback (TLFB)	28
3.3 The Inventory of Drug Use Consequences (InDUC-2L)	30

3.4	Social Support	30
3.5	Treatment History	31
3.6	Brief Situational Confidence Questionnaire (BSCQ)	32
3.7	Motivation to Change	32
4	Treatment	35
4.1	Methods of Treatment	35
4.1.1	Empirically Supported Treatments (ESTs)	35
4.1.2	Harm Reduction, Drug Safety, and Abstinence.	36
4.2	Efficacy and Prognosis	42
4.3	The Therapeutic Alliance as a Mechanism of Action	43
4.4	Variations and Combinations of Methods	44
4.4.1	The Spirit of Motivational Interviewing	44
4.4.2	Mutual-Help and Self-Help Groups	50
4.4.3	Mindfulness Meditation.	55
4.4.4	Psychopharmacological Adjuncts to Treatment	57
4.5	Readiness to Change, Therapist Goals, and Problems in Carrying Out the Treatment.	60
4.5.1	Interventions Tailored to Motivation.	60
4.5.2	Readiness to Change and Motivation	60
4.5.3	Ambivalent About Change	61
4.5.4	Envisioning	64
4.5.5	Increased Readiness	64
4.5.6	Change Strategy	65
4.5.7	Avoiding Classically Conditioned Stimuli	65
4.5.8	Alternative Activities	66
4.5.9	Altering Beliefs	66
4.5.10	Generalizing Challenges to Maladaptive Cognitions	68
4.5.11	Implementing Change	68
4.5.12	Maintenance.	69
4.5.13	Lapse and Relapse	69
4.5.14	Abstinence Violation	71
4.5.15	Apparently Irrelevant Decisions	71
4.5.16	High-Risk Situations	71
4.6	Multicultural Issues	77
5	Further Reading	79
6	References	81
7	Appendix: Tools and Resources	91

Description

1.1 Terminology

This first section reviews diagnostic terms, epidemiology, prognosis, differential diagnosis, comorbidities, and diagnostic procedures for drug-related problems. A clear understanding of each of these topics will lay a foundation for efficient assessment and treatment.

1.1.1 Diagnostic Terms

Defining problem drug use can seem like a fool's errand. Some people clearly have their lives altered by their use of psychoactive substances; others seem to use without troubles. The range of substances, intoxication experiences, and negative consequences is vast. Several terms appear to describe drug problems adequately, but many others are imprecise, ambiguous, or pejorative. The definition of problematic use reflects tacit assumptions about drugs and drug users. These assumptions can alter our interactions with clients in ways that may escape our awareness. Those who consider illicit drug use (or any illegal behavior) inherently wrong can find that their interactions with these clients differ dramatically from their interactions with other clients. The moral implications of using drugs change in different environments and different eras. Perhaps the best perspective for defining problem drug use requires understanding the goal of the definition. Ideally, identifying drug problems could serve as a step toward building a productive therapeutic relationship. Precise names for these problems can also aid communication within a treatment team. When everyone involved gives the same meaning to terms like *addiction* or *substance use disorder*, it is easier to avoid confusion.

Categories and Continua

Many used the term *addict* without a formal definition for years, which often led to misunderstandings. *Dependence* and *abuse* had specific meanings with acceptable discriminant validity, giving them the potential to improve communication, but subsequent research revealed that they seemed to stem from a single, underlying factor dubbed *substance-related and addictive disorders*. Recent work focuses on adapting substance-related and addictive disorders to provide a convenient way for clinicians and researchers to communicate. Nevertheless, two people with this diagnosis may not share a single symptom. A rigid focus on these diagnostic categories can also lead clinicians to miss a chance to prevent problems before they start. A client experiencing negative

Substance misuse
problems can lie
along a continuum

consequences unrelated directly to the chosen symptoms might not qualify for a diagnosis, or at least not a severe one, but could still benefit from altering drug use. Thus, thinking about the impact of drugs on quality of life can prevent problems in a way that a premature focus on diagnoses might neglect.

Unfortunately, lay conceptions of diagnostic categories confuse both clients and the public. For example, some people define any use of an illegal drug as problematic, but busy clinicians rarely have time to split hairs over who does or does not qualify for a label. Perhaps the best approach to defining misuse relies on cataloging problems that stem from the drug. This approach may provide the most specific information for treatment. Many view drug problems categorically – either substance use interferes with someone’s life or it does not. Nevertheless, examining drug problems on a continuum has considerable utility and empirical support (Denson & Earleywine, 2006). One useful way to look at this range of troubles would place complete abstinence on one end of a continuum and serious troubles, including a diagnosis of severe substance use disorder, on the other. Unfortunately, the word *abstinence* has some odd connotations. People who do not use a drug might not be showing some effortful attempts to abstain. They might not show any interest. *Non-use* remains an awkward alternative but gets the meaning across. Nonproblematic use might fall near the abstinence end of the continuum, while troubles that might not qualify for a diagnosis might lie closer to the diagnosable disorder. Variation within substance use disorder is also acknowledged, from mild to severe, depending upon the number of symptoms. This continuous model might challenge those of us trained in the tradition of diagnosis or disease, but could also heighten awareness for the prevention of problems (see Figure 1). This continuous approach is also consistent with the reformulation of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5; American Psychiatric Association, 2013).

